# FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/genetics/generalgenetics/123945) · 2026-11-18 · Medicine
Page: https://themorning.science/story/fda-oks-drug-linked-to-longer-survival-in-fatal-genetic-disorder-579861bbb9160c4d
Kind: launch · Impact: medium

## In brief

- The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC).
- NPC is described as a rare and fatal genetic disorder.
- The approval is indicated for adults and children weighing at least 15 lb; the source snippet is truncated before the full indication.

## Why it matters

This is the first approval of a treatment for infantile-onset NPC, a rare fatal disorder, and the reported link to longer survival could matter for clinicians and families managing the disease.

## Timeline

- 2026-11-17: FDA approves adrabetadex (Lembaz) injection for infantile-onset Niemann-Pick disease type C

## Coverage

- [FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder](https://www.medpagetoday.com/genetics/generalgenetics/123945) — MedPageToday.com - medical news for physicians, 2026-11-18

Tags: fda approval, niemann-pick, rare disease, genetic disorders, drugs

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
